Tests magnetic brain stimulation after stroke clot removal treatment
Tests magnetic brain stimulation against a sham treatment in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
Key facts
- Where
- Xi'an, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who had an acute stroke in the front part of the brain and have just had a procedure to remove the clot. It tests magnetic stimulation of the brain against a sham (fake) treatment.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke in the anterior circulation, caused by a blocked terminal internal carotid artery or M1/M2 segment of the middle cerebral artery. Head CT within 24 hours of onset shows an ASPECT score ≥6. NIHSS score before thrombectomy is between 6 and 25.
- Earlier treatment
- Must have had endovascular thrombectomy that reopened the vessel (mTICI > 2b/3). Must not have taken part in another interventional study within 30 days before this study or after the onset of this condition.
Main reasons for not taking part
- Metal objects in the head, pacemaker, implanted drug pump or cochlear implant
- Epilepsy, raised pressure in the head, tumor, acute brain bleeding or other severe nervous system disease
- Severe heart, liver or kidney problems
- Stroke on both sides of the brain, or midline shift or major mass effect on head scan
- Pregnant or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06639360, who can take part
Where in China
- Xijing hospitalXi'an, ChinaContact: Jingjing Zhao, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT06639360
- Record updated
- 4 December 2025
- Original description
This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.Read full original descriptionShow less
Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.
Inclusion: Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old; Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery; A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy; Pre-stroke mRS score is ≤1; NIHSS score before thrombectomy is between 6 and 25; With vascular recanalization of mTICI > 2b/3; Informed consent form signed.
Exclusion: Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc; Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention; Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition; Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys; Patients with severe mental disorders or dementia who cannot cooperate with follow-up; Patients with other severe diseases resulting in an expected survival of less than 90 days; Head CT/MRI suggests acute cerebral infarction in both sides; Patients who are pregnant or breastfeeding; Patients who cannot cooperate with informed consent.